1. Argentina Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Laboratorios Richmond S.A.C.I.F.

Laboratorios Richmond S.A.C.I.F.

RICH.BA
Laboratorios Richmond S.A.C.I.F.AR flagBuenos Aires Stock Exchange
1,585.00
ARS
- -
- -
127.99BMarket Cap
Laboratorios Richmond S.A.C.I.F.
RICH.BA
(Buenos Aires Stock Exchange)

Recent

price

1,585.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
28.09
34.64
65.56
115.56
400.88
711.99
1,052.49
1,495.38
1,569.38
1,530.82
Revenue per Share
0.86
-4.11
1.96
9.09
14.27
6.3
-292.62
388.45
38.24
223.53
Basic EPS, GAAP
-1.72
-7.08
-5.65
-13.61
-52.94
-455.05
-393.81
-51.92
-649.71
-392.86
Free Cash Flow per Basic Share
0.71
0.26
- -
- -
1.44
8.44
- -
- -
32.58
4.07
Dividend per Share
7.03
2.44
5.28
17.07
42.45
94
-291.62
254.78
41.48
307.33
Book Value per Share
18.25
15.71
25.5
45.35
81.58
226.06
201.08
571.98
562.14
853.36
Tangible Book Value per Share
57
81
81
81
81
81
81
81
81
81
Basic Weighted Avg Shares
1,591
2,795
5,303
9,330
32,366
57,518
84,989
120,754
126,726
123,615
Sales/Revenue/Turnover
12.41
6.25
20
24.89
13.81
16.13
13.43
17.44
26.13
22.08
Operating Margin (%)
51
82
186
255
673
2,279
5,082
9,569
10,568
10,895
Depreciation Expense
49
-332
159
734
1,152
509
-23,629
31,368
3,088
18,050
Net Income, GAAP
53.4
- -
40.28
35.87
57.57
80.06
- -
16.68
73.6
28.49
Effective Tax Rate (%)
3.06
-11.87
2.99
7.87
3.56
0.88
-27.8
25.98
2.44
14.6
Profit Margin (%)
943
1,103
906
2,802
11,899
15,589
-10,688
15,500
742
-2,440
Working Capital
38
148
152
1,481
18,814
57,732
18,020
164,485
186,580
176,962
LT Debt
1,253
1,709
2,791
5,202
10,471
31,818
49,982
85,966
93,039
122,241
Total Equity
- -
- -
21.64
25.67
9.19
2.82
- -
9.74
2.84
7.92
Return on Invested Capital (%)
- -
- -
25.5
40.76
11.64
2.8
- -
34.25
3.16
17.3
Return on Capital (%)
- -
-111.4
50.84
81.34
47.95
9.24
- -
- -
25.81
75.98
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
35,363
59,804
58,824
LT Borrowings
159,925
166,365
157,548
LT Finance Leases
18,037
20,214
19,415
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
81
81
81
Market Capitalization
83,982
159,484
134,047

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
94,087
120,538
111,178
Cash, Cash Equivalents & STI
3,916
14,466
3,238
Accounts Receivable, Net
33,495
58,563
59,272
Inventories
40,019
41,666
43,692
Total Current Liabilities
89,768
119,795
113,619
Payables & Accruals
- -
- -
- -
ST Debt
35,363
59,804
58,824
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
88.49%
8.23%
Free Cash Flow
- -
419.99%
1,151.36%
Net Income, GAAP
- -
-1,012.92%
-90.16%
Sales/Revenue/Turnover
- -
83.88%
4.95%
Total Cash Common Dividend
- -
- -
285.94%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22,416
23,644
25,971
33,954
120,754
2025
35,828
25,178
30,878
38,816
126,726
2026
28,744
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
132.8
51.08
90.59
- -
388.45
2025
93.03
-34.82
-113.57
- -
38.24
2026
262.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
1.7
- -
32.58
2026
- -
- -
- -
- -
- -
Similar Companies
BioGaia AB (publ) (BIOGY)
Indivior Pharmaceuticals Inc (INDV.L)
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ)
Camarico Investment Group Ltd. (CIG.CN)
Wakamoto Pharmaceutical Co.,Ltd. (4512.T)
Dermapharm Holding SE (DMPHF)
Business
Laboratorios Richmond S.A.C.I.F. (RICH.BA) develops and manufactures pharmaceutical products including generics, biosimilars, and licensed technologies; its core portfolio encompasses antiretroviral treatments for HIV, oncology and oncohematology drugs, cardiometabolic therapies such as antihypertensives (Losartan/Tacardia, Telmisartan/Telcardia), hypolipidemics (Atorvastatin/Vastina), diuretics, antiplatelet agents and hypoglycemics, neurological and psychiatric medications including analgesics, antipsychotics, antidepressants, anti-dementia drugs, antiepileptics, hypnotics and multiple sclerosis treatments, as well as ophthalmological solutions like Ganciclovir and innovative fixed-dose combinations in user-friendly packaging. Founded in 1935 and headquartered in Buenos Aires, Argentina, with manufacturing facilities in Pilar, Argentina, and Bogotá, Colombia, plus commercial operations in Chile, Paraguay, Mexico and Uruguay, the company serves physicians, pharmacists, health institutions and patients across 25 countries in Latin America, Africa, Asia and the Middle East. In July 2024, Laboratorios Richmond launched Yriviak, its bevacizumab similar biological for neovascular age-related macular degeneration, marking its second such product and first in ophthalmology following ANMAT approval in November 2023; the company also secured approval for adalimumab similar biological Armixa in December 2023, with launch planned soon after, while continuing technology transfers and regional expansions including a new entity in Uruguay.